Brokerages Set Mazor Robotics Ltd – (MZOR) PT at $45.67

Mazor Robotics Ltd – (NASDAQ:MZOR) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $45.67.

MZOR has been the subject of several analyst reports. BidaskClub lowered shares of Mazor Robotics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Zacks Investment Research lowered shares of Mazor Robotics from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Barclays reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Mazor Robotics in a research report on Wednesday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Tuesday, November 7th. Finally, Ladenburg Thalmann Financial Services set a $67.00 price objective on shares of Mazor Robotics and gave the company a “buy” rating in a research report on Monday, October 30th.

Institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc raised its position in Mazor Robotics by 87.2% during the 4th quarter. IFP Advisors Inc now owns 2,275 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 1,060 shares during the last quarter. Advisor Group Inc. raised its position in Mazor Robotics by 365.8% during the 3rd quarter. Advisor Group Inc. now owns 2,795 shares of the medical instruments supplier’s stock worth $138,000 after buying an additional 2,195 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in Mazor Robotics by 107.3% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,811 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 1,973 shares during the last quarter. Quantbot Technologies LP purchased a new position in Mazor Robotics during the 2nd quarter worth approximately $135,000. Finally, Halbert Hargrove Russell LLC purchased a new position in Mazor Robotics during the 3rd quarter worth approximately $214,000. 26.37% of the stock is owned by hedge funds and other institutional investors.

Mazor Robotics (NASDAQ:MZOR) traded down $0.04 during mid-day trading on Friday, hitting $64.68. 202,007 shares of the company’s stock traded hands, compared to its average volume of 536,271. The stock has a market capitalization of $1,770.00, a price-to-earnings ratio of -91.20 and a beta of 1.16. Mazor Robotics has a 1-year low of $21.21 and a 1-year high of $69.37.

Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.19. Mazor Robotics had a negative net margin of 28.80% and a negative return on equity of 22.68%. sell-side analysts forecast that Mazor Robotics will post -0.72 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Mazor Robotics Ltd – (MZOR) PT at $45.67” was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2018/02/05/brokerages-set-mazor-robotics-ltd-mzor-pt-at-45-67.html.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply